Envoy Medical Stock Price, News & Analysis

Envoy Medical (NASDAQ: COCH) received FDA approval on October 7, 2025 to expand its pivotal trial for the fully implanted Acclaim cochlear implant to the final stage based on promising three-month data from the first 10 patients.

All 10 participants reached the three-month milestone with no serious adverse events or unanticipated device effects. The company now expects full enrollment by early 2026, has moved timelines up 3–6 months, and reduced anticipated capital needs by $10–$15 million.

Envoy Medical (NASDAQ:COCH), a hearing health company specializing in fully implanted hearing solutions, has announced its participation in the upcoming American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) conference. The event will take place on October 11th-14th, 2025 in Indianapolis, IN.

During the conference, the company will conduct individual meetings with implanting surgeons at booth #1108 to discuss recent product developments. Interested attendees can schedule meetings via info@envoymedical.com.

Envoy Medical (NASDAQ: COCH), a hearing health company, has closed its previously announced registered direct offering, raising $2.5 million through the sale of 1,908,402 shares of Class A common stock at $1.31 per share.

The company also conducted a concurrent private placement of unregistered warrants to purchase up to 5,725,206 shares at an exercise price of $1.31 per share. If fully exercised, these warrants could provide additional gross proceeds of $7.5 million. The warrants will be exercisable after stockholder approval and expire 24 months thereafter.

H.C. Wainwright & Co. served as the exclusive placement agent, and Envoy Medical plans to use the net proceeds for working capital and general corporate purposes.

Envoy Medical (NASDAQ: COCH) is advancing commercialization plans for its breakthrough Acclaim® fully implanted cochlear implant while its FDA pivotal trial progresses successfully. The trial has reached significant milestones with all patients completing three-month follow-ups with no serious adverse events, and six-month follow-ups now underway.

The company plans to establish 30-40 clinical sites upon FDA approval, focusing on excellence and strong foundation building. The Acclaim device, which received FDA Breakthrough Device Designation in 2019, is targeting PMA submission in 2027. Envoy Medical aims to tap into an underserved market segment of individuals who haven't adopted traditional hearing loss treatments.

Envoy Medical (NASDAQ: COCH), a hearing health company, has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will issue 1,908,402 shares of Class A common stock at $1.31 per share.

Additionally, in a concurrent private placement, Envoy will issue unregistered warrants to purchase up to 5,725,206 shares at an exercise price of $1.31 per share. If these warrants are fully exercised, the company could receive additional gross proceeds of approximately $7.5 million. H.C. Wainwright & Co. is serving as the exclusive placement agent, with the offering expected to close around September 23, 2025.

Envoy Medical (NASDAQ: COCH) has been granted European Patent No. 4338791 for its innovative cochlear implant technology, effective September 17, 2025. The patent specifically covers systems and methods for compensating for variability in middle ear sensors using analog and digital signals.

This patent adds to Envoy Medical's recent patent acquisitions in the United States, Australia, and Hong Kong. The technology relates to their investigational Acclaim® Cochlear Implant, which uniquely eliminates external microphones and hardware by leveraging the natural ear, potentially transforming treatment for severe to profound sensorineural hearing loss.

Envoy Medical (NASDAQ: COCH), a hearing health company, has announced significant achievements in Q3 2025. The company has completely eliminated over $32 million in debt, strengthening its balance sheet and capital structure. Envoy has expanded its global patent portfolio with 7 new patents across the U.S., Australia, and Hong Kong, now holding approximately 38 U.S. and 40 foreign patents.

The company reported positive progress in its pivotal clinical trial for the Acclaim® fully implanted cochlear implant, with all 10 initial patients completing three-month follow-ups without serious adverse events. Additionally, five new Category III CPT codes for totally-implantable active middle ear implants, including their FDA-approved Esteem® device, took effect on July 1, 2025, potentially improving reimbursement opportunities.

Envoy Medical (NASDAQ: COCH) has secured four new global patents, strengthening its position in fully implantable hearing technology. The patents include three Australian patents and one U.S. patent, focusing on programming cochlear implant accessories, lead characterization, and integrated signal analysis functionality.

These patents enhance Envoy Medical's ability to develop and protect innovations for next-generation cochlear implant solutions that offer patients a discreet, 24/7 hearing experience without external components. CEO Brent Lucas emphasized that these patents represent a crucial step in strengthening their global intellectual property portfolio and advancing their mission to deliver transformative hearing solutions.

Envoy Medical (NASDAQ: COCH), a hearing health company specializing in fully implanted hearing solutions, announced that CEO Brent Lucas will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference taking place from September 8-10, 2025, in New York City.

The presentation is available on-demand through the company's investor relations website and can be accessed via a direct link. Interested parties can join Envoy Medical's email distribution list by contacting Envoy@kcsa.com with COCH in the subject line.